Pulmatrix Regains Rights to PUR1800 for COPD, Phase 2 Trial Planned
Pulmatrix will regain full rights to its portfolio of narrow spectrum kinase inhibitor (NSKI) medications, including the investigational therapy PUR1800 to treat acute flare in chronic obstructive pulmonary disease (COPD) and other chronic diseases of the airways.